<DOC>
	<DOCNO>NCT01003990</DOCNO>
	<brief_summary>The purpose study provide atazanavir tenofovir-emtricitabine HIV-infected subject complete atazanavir tenofovir-emtricitabine therapy previous BMS sponsor clinical trial</brief_summary>
	<brief_title>Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access</brief_title>
	<detailed_description>Provide study drug patient roll BMS ATV clinical trial country medication commercially available .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Subjects must provide write informed consent Currently receive atazanavir ( unboosted boost 100 mg ritonavir QD ) and/or tenofoviremtricitabine time screen viral load ≤ 10,000 copies/mL therapy Subjects receive investigational antiretroviral agent Expanded Access Programs allow participate follow discussion approval BMS Medical Monitor ≥ 16 year age ( minimum age determine local regulatory legal requirement dictate ) Both female childbearing potential male must utilize effective barrier contraception reduce transmission sexually transmitted disease , include HIV . Other contraception addition barrier method permit , however interaction atazanavir oral contraceptive study WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 8 week study WOCBP use prohibit contraceptive method ( contraceptive method prohibit study . However , caution warrant coadministration oral contraceptive ) Women pregnant breastfeed Women positive pregnancy test enrollment prior study drug administration , exception woman roll AI424182 , may still positive βHCG test time enrollment All subject previously discontinue atazanavir study reason Active alcohol substance abuse sufficient , Investigator 's opinion , prevent adequate compliance study therapy increase risk develop pancreatitis chemical hepatitis Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study , unable comply dose requirement Any follow laboratory value : ) Serum creatinine ≥ 1.5 time upper limit normal , b ) Liver enzymes ( AST , ALT ) ≥ 5 time upper limit normal , Hypersensitivity component formulation study drug Refer Section 6.4.1 detail prohibit therapy Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Treatment experience</keyword>
</DOC>